Slit2 expression and its correlation with subcellular localization of β-catenin in gastric cancer

Shi,Rongliang; Liu,Weiyan; Liu,Bingya; Xu,Ziping; Chen,Liping; Zhang,Ziping

doi:10.3892/or.2013.2662

Slit2 expression and its correlation with subcellular localization of β-catenin in gastric cancer

Authors:
- Rongliang Shi
- Weiyan Liu
- Bingya Liu
- Ziping Xu
- Liping Chen
- Ziping Zhang
View Affiliations

Affiliations: Department of General Surgery, Central Hospital of Shanghai Minhang District, Shanghai 201100, P.R. China, Department of General Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200025, P.R. China
Published online on: August 7, 2013 https://doi.org/10.3892/or.2013.2662
Pages: 1883-1889

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer is the fourth most common cancer worldwide. Several signaling pathways are involved in gastric cancer development and progression. Slit2 was recently found to be involved in cancer; however, its expression pattern in gastric cancer has not been discovered yet. In the present study, we investigated the expression of Slit2 in human gastric cancer and its correlation with the expression and subcellular localization of β-catenin. Immunohistochemistry (IHC) staining revealed that Slit2 was highly expressed in human gastric cancer tissues, while it was low or weakly expressed in normal gastric tissues. The differences in clinicopathological features between different groups were determined using Pearson's χ2 test. Slit2 levels were significantly associated with differentiation, Lauren's classification, lymph node metastasis and TNM staging. Slit2 levels were positively correlated with β-catenin level in gastric cancer tissues and cell lines. High levels of Slit2 were correlated with the membrane localization of β-catenin, and low levels of Slit2 were correlated with nuclear translocation of β-catenin in both gastric cancer tissues and cell lines assayed by IHC and immunofluorescence staining, respectively. Our data suggest that Slit2 was highly expressed in gastric cancer patients with less advanced clinicopathological features. Slit2 levels were correlated with β-catenin level and subcellular localization.

View Figures

View References

1	Brenner H, Rothenbacher D and Arndt V: Epidemiology of stomach cancer. Methods Mol Biol. 472:467–477. 2009. View Article : Google Scholar
2	Du C, Zhou Y, Cai H, Zhao G, Fu H and Shi YQ: Poor prognostic factors in patients with stage I gastric cancer according to the seventh edition TNM classification: a comparative analysis of three subgroups. J Surg Oncol. 105:323–328. 2012. View Article : Google Scholar : PubMed/NCBI
3	Lazar D, Taban S, Sporea I, et al: Gastric cancer: correlation between clinicopathological factors and survival of patients (III). Rom J Morphol Embryol. 50:369–379. 2009.PubMed/NCBI
4	Lazar D, Taban S, Sporea I, et al: Gastric cancer: correlation between clinicopathological factors and survival of patients. II. Rom J Morphol Embryol. 50:185–194. 2009.PubMed/NCBI
5	Macias H, Moran A, Samara Y, et al: SLIT/ROBO1 signaling suppresses mammary branching morphogenesis by limiting basal cell number. Dev Cell. 20:827–840. 2011. View Article : Google Scholar : PubMed/NCBI
6	Georgas K, Burridge L, Smith K, et al: Assignment of the human slit homologue SLIT2 to human chromosome band 4p15.2. Cytogenet Cell Genet. 86:246–247. 1999. View Article : Google Scholar : PubMed/NCBI
7	Jia L, Cheng L and Raper J: Slit/Robo signaling is necessary to confine early neural crest cells to the ventral migratory pathway in the trunk. Dev Biol. 282:411–421. 2005. View Article : Google Scholar : PubMed/NCBI
8	Wong K, Park HT, Wu JY and Rao Y: Slit proteins: molecular guidance cues for cells ranging from neurons to leukocytes. Curr Opin Genet Dev. 12:583–591. 2002. View Article : Google Scholar : PubMed/NCBI
9	Goldberg D, Borojevic R, Anderson M, Chen JJ, Gershon MD and Ratcliffe EM: Slit/Robo-mediated chemorepulsion of vagal sensory axons in the fetal gut. Dev Dyn. 242:9–15. 2013. View Article : Google Scholar : PubMed/NCBI
10	Mitra S, Mazumder-Indra D, Mondal RK, et al: Inactivation of SLIT2-ROBO1/2 pathway in premalignant lesions of uterine cervix: clinical and prognostic significances. PLoS One. 7:e383422012. View Article : Google Scholar : PubMed/NCBI
11	Dong R, Yu J, Pu H, Zhang Z and Xu X: Frequent SLIT2 promoter methylation in the serum of patients with ovarian cancer. J Int Med Res. 40:681–686. 2012. View Article : Google Scholar : PubMed/NCBI
12	Alvarez C, Tapia T, Cornejo V, et al: Silencing of tumor suppressor genes RASSF1A, SLIT2, and WIF1 by promoter hypermethylation in hereditary breast cancer. Mol Carcinog. 52:475–487. 2012.
13	Jin J, You H, Yu B, et al: Epigenetic inactivation of SLIT2 in human hepatocellular carcinomas. Biochem Biophys Res Commun. 379:86–91. 2009. View Article : Google Scholar : PubMed/NCBI
14	Dallol A, Morton D, Maher ER and Latif F: SLIT2 axon guidance molecule is frequently inactivated in colorectal cancer and suppresses growth of colorectal carcinoma cells. Cancer Res. 63:1054–1058. 2003.PubMed/NCBI
15	Dunwell TL, Dickinson RE, Stankovic T, et al: Frequent epigenetic inactivation of the SLIT2 gene in chronic and acute lymphocytic leukemia. Epigenetics. 4:265–269. 2009. View Article : Google Scholar : PubMed/NCBI
16	Singh RK, Indra D, Mitra S, et al: Deletions in chromosome 4 differentially associated with the development of cervical cancer: evidence of slit2 as a candidate tumor suppressor gene. Hum Genet. 122:71–81. 2007. View Article : Google Scholar : PubMed/NCBI
17	Ma S, Liu X, Geng JG and Guo SW: Increased SLIT immunoreactivity as a biomarker for recurrence in endometrial carcinoma. Am J Obstet Gynecol. 202:68.e61–68.e11. 2010.PubMed/NCBI
18	Shen F, Liu X, Geng JG and Guo SW: Increased immunoreactivity to SLIT/ROBO1 in ovarian endometriomas: a likely constituent biomarker for recurrence. Am J Pathol. 175:479–488. 2009. View Article : Google Scholar : PubMed/NCBI
19	Prasad A, Paruchuri V, Preet A, Latif F and Ganju RK: Slit-2 induces a tumor-suppressive effect by regulating β-catenin in breast cancer cells. J Biol Chem. 283:26624–26633. 2008.PubMed/NCBI
20	Chen WF, Gao WD, Li QL, Zhou PH, Xu MD and Yao LQ: SLIT2 inhibits cell migration in colorectal cancer through the AKT-GSK3β signaling pathway. Int J Colorectal Dis. Jan 13–2013.(Epub ahead of print).
21	Liu X, Lu Y, Zhang Y, et al: Slit2 regulates the dispersal of oligodendrocyte precursor cells via Fyn/RhoA signaling. J Biol Chem. 287:17503–17516. 2012. View Article : Google Scholar : PubMed/NCBI
22	Hofmeister W, Devine CA, Rothnagel JA and Key B: Frizzled-3a and slit2 genetically interact to modulate midline axon crossing in the telencephalon. Mech Dev. 129:109–124. 2012. View Article : Google Scholar
23	Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ and Levin B: bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI
24	Chang PH, Hwang-Verslues WW, Chang YC, et al: Activation of Robo1 signaling of breast cancer cells by Slit2 from stromal fibroblast restrains tumorigenesis via blocking PI3K/Akt/β-catenin pathway. Cancer Res. 72:4652–4661. 2012.PubMed/NCBI